Description

Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer[1][2].—Metabolism-protein/nucleotide metabolism–C59H84N18O14—-[1]Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39(3): 1034–1042.|[2]Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32.–65807-02-5–1269.41046—-O=C([C@@H](N1)CCC1=O)N[C@@H](CC2=CNC=N2)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](COC(C)(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N3[C@@H](CCC3)C(NNC(N)=O)=O)=O)=O)=O)=O)CC4=CC=C(O)C=C4)=O)=O)CC5=CNC6=C5C=CC=C6)=O–Cancer; Endocrinology–10 mM in DMSO–Apoptosis;GnRH Receptor—-Apoptosis;GPCR/G Protein–Peptides